Sangamo swell

Sangamo BioSciences Inc. (NASDAQ:SGMO) shares have more than doubled over the past few months thanks to a deal with Biogen Idec Inc. (NASDAQ:BIIB) and a steady flow of data. While the gene therapy play does not have obvious upcoming catalysts, at least one investor believes Sangamo's platform will continue to drive momentum.

Sangamo is using its zinc finger nuclease (ZFN) genome-editing technology to develop therapeutics...